Low H1 revenue, but progress behind the scenesTarget: SEK 1bn company by 2030, with 25% recurring re...
Late Wednesday evening KebNi announced that it has raised SEK 29.
Carlsquare Equity Research kommenterar förväntingarna inför Spotlight Groups kv2-rapport den 14 augu...
Redeye will keep its positive view of Transtema following a softer Q2 than expected but with slightl...
Relais reported Q2 adjusted EBITA of EUR 4.8m, 3% below Refinitiv consensus and 13% below our estima...
Boreo reported Q2 adjusted EBIT ex-PPA of EUR 2.4m, 31% above our estimate and 20% above Refinitiv c...
Carlsquare Equity Research har kommenterat förväntningarna inför Future Gamings kv2 rapport den 24 a...
Tessin, med en digital investeringsplattform för fastigheter, redovisade en nettoomsättning om 12,6 ...
Aspo’s Q2 results fell short of estimates especially due to the loss-making Supramax vessels and cer...
Sales SEK +0.8m and adj. EBIT -7% vs. ABGSCeMultiple Freemelt ONE orders taking longer to land, but ...
Suominen should make further progress towards restoring profitability in H2, however Q2 results rema...
Group net sales was EUR 29m in Q2 (Nordea EUR 31m).
Sales in line, EBIT +11% vs. ABGSCe, FX drivenOrganic growth -10% vs ABGSCe -8.
Redeye makes minor forecast changes following Bredband2’s Q2 2023 report, in which sales came in sli...
Redeye updates its estimates after reviewing Fantasma Games’ Q2 report, which showed lower growth th...
Redeye updates its estimates and fair value range following FlexQube’s Q2 report, where sales exceed...
Redeye initiates coverage of Lytix Biopharma, an immuno-oncology company with a Nobel Prize Laureate...
• EBITA up 17% y-o-y, 14% ahead of ABGSCe • We lift '23e-'25e EBITA by 5-4% • 10x '23e EV/EBITA, eas...
Redeye provides an update after Gasprox’s Q2’23 report.
Svagare marknad i USA och Europa påverkade försäljningen och resultatet negativt i Q2.
